<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ900618-0050</DOCNO><DOCID>900618-0050.</DOCID><HL>   Technology Brief -- ICN Pharmaceuticals Inc.:   Ireland Authorizes Using   Ribavirin on HIV Patients</HL><DATE>06/18/90</DATE><SO>WALL STREET JOURNAL (J), PAGE B4</SO><CO>   ICN</CO><IN>DRUG MANUFACTURERS (DRG)</IN><LP>   ICN Pharmaceuticals Inc. said Ireland's Department ofHealth authorized the company to market the anti-viral drugribavirin for use in the &quot;management&quot; of patients infectedwith the human immunodeficiency virus and other conditionsrelated to acquired immune deficiency syndrome.   The approval, the Costa Mesa, Calif., company said, marksthe first time that a country has authorized the anti-viraldrug specifically for the treatment of HIV-infected patients.Ribavirin already is used in the U.S. and in 16 other nationsfor the treatment of infants and young children with severerespiratory tract infections caused by respiratory syncytialvirus. Ribavirin is used in more than 30 additional countriesto treat other viral infections.</LP><TEXT>   ICN recently withdrew its request for U.S. governmentapproval to market ribavirin for the treatment of the HIVvirus.   There were about 100 cases of AIDS in Ireland in 1989, andabout half of those victims have since died, according to anICN spokesman. He said researchers predict the number of AIDSpatients in Ireland will reach 12,000 by 1995.</TEXT></DOC>